The Week

Bristol Myers Squibb (BMY) fell 4.76% this week to close at $63.64, underperforming the S&P 500 by around 3.96 percentage points. The shortened four-session week was steady selling pressure: shares opened at $65.66 on Tuesday, touched a high of $65.893, then slipped about 3.2% that day. Wednesday and Thursday closed lower again, and Friday saw an intraday low of $63.27 before settling at $63.64. Weekly amplitude was 3.99%, while average daily volume of 7.41 million shares ran roughly 25% below the prior median.

Key Events

The main development was positive topline data from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR-T therapy for relapsed/refractory multiple myeloma. The readout landed on Tuesday evening, yet the stock slid 3.25% that same day, with the price action not aligned with the trial result. Also this week, BMY launched a new paediatric multiple sclerosis study for Ozanimod, designed to compare directly against Fingolimod. On Wednesday, both Novartis and Bristol Myers paused autoimmune CAR-T studies, cooling sentiment across the segment. No material company filings were submitted during the week.

Analyst Ratings

Among the 29 institutions covering Bristol Myers Squibb, 7 rate it buy, 3 rate it overweight, 17 rate it hold, 1 rates it underweight, 1 rates it sell, and 1 has no opinion. The consensus rating is buy, with a consensus target of $66.42, about 4.4% above the latest price of $63.64. The target range is wide — from $40 to $80 — pointing to divergent views on the long-term outlook. Within pharmaceuticals, BMY ranks 2nd among 206 companies, placing it near the top of the peer group.

The Week Ahead

The coming week is mostly about macro data. The New York Fed manufacturing index lands on Tuesday, 15 September, followed by a batch of retail sales figures and the NAHB housing market index on Wednesday, 16 September. On the company side, Bristol Myers’ fiscal Q3 2026 results are scheduled for Thursday, 29 October, before the open, where management may offer more detail on pipeline progress and the CAR-T strategy.

In Short

This week delivered mixed CAR-T signals — positive trial data alongside study halts — and the stock answered with a 4.76% weekly decline. The consensus rating remains buy and the consensus target sits above spot, but the distance between the low and high targets stretches to $40, reflecting wide disagreement. Valuation shows a P/E of roughly 14x and a dividend yield near 3.94%; on the latest session, large-lot money was a net buyer while mid- and small-lot flows were net sellers. What comes next is whether CAR-T clinical and regulatory progress can rebuild conviction, and what the late-October earnings update says about the pipeline.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.